Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.25 USD | +4.50% | -16.67% | -76.10% |
Mar. 20 | Longeveron to Effect 1-for-10 Reverse Stock Split | MT |
Feb. 27 | Transcript : Longeveron Inc., 2023 Earnings Call, Feb 27, 2024 |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-76.10% | 8.17M | - | - | |
+9.30% | 46.03B | B | ||
+52.73% | 44.55B | A | ||
+7.15% | 40.8B | B- | ||
-8.78% | 28.25B | C | ||
+18.68% | 27.71B | B- | ||
-21.92% | 18.82B | B | ||
+14.62% | 13.91B | C+ | ||
+31.85% | 12.43B | C+ | ||
-8.77% | 11.06B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Longeveron Inc. - Nasdaq
- Ratings Longeveron Inc.